SRPT

13.3775.60%
MK

M. Kathleen Behrens Wilsey

Independent Chairwoman

Dr. M. Kathleen Behrens Wilsey, Ph.D, was Director of MiMedx Group, Inc. from June 18, 2025 until June 10, 2026 and served as its Chairman of the Board. She serves as a Consultant at RS Investments. She served as an Advisor of Physic Ventures, LLC. She served at Robertson Stephens & Co., where she served as a General Partner and Managing Director and also served as Securities Analyst and Venture Investor focusing on life sciences investments. In 1988, she joined the venture capital group of Robertson Stephens & Co. and helped found Protein Design Laboratories, Inc. and COR Therapeutics, Inc. From January 2012 to June 2014, she was the Co-Founder, President, Chief Executive Officer and director of the KEW Group, a private oncology services company. Dr. Behrens served on the board of directors of Amylin Pharmaceuticals, a biopharmaceutical company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. Dr. Behrens has been the Chairwoman of the Board of Directors at Sarepta Therapeutics, Inc. since April 2015. She served as the President, Chairperson and Director of the National Venture Capital Association. Dr. Behrens has been a Director of AVI Biopharma, Inc., March 31, 2009. Dr. Behrens has been Director of Sarepta Therapeutics, Inc. since March 2009. Dr. Behrens served as a Director of Abgenix, Inc. from 2001 to 2006. She served as a Director of Protein Design Labs, Inc., Cell Genesys, Inc., InSite Vision, Inc. and COR Therapeutics, Inc. Dr. Behrens served as a Director of Science, Technology and Economic Policy for the National Research Council from 1997 to 2005 and was a member of the Institute of Medicine Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer. She has been a Member of the J. David Gladstone Institute’s Advisory Council since 2003. She serves on the President's Council of Advisors on Science and Technology. Dr. Behrens holds a Bachelor of Science (B.S.) in Biology and a Ph.D. in Microbiology from the University of California, Davis, where she performed genetic research for six years. Dr. Behrens has significant experience in the financial services and biotechnology sectors, as well as in healthcare policy. She served as Independent Director at IGM Biosciences Inc. since January 2019 until August 14, 2025.

Positions